Safety and Immunogenicity of Penbraya (MenABCWY) vs Trumenba + Menveo in Adolescents

Phase 3, randomised, single-blind trial of Meningococcal ABCYW vaccine in meningococcal disease (4 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= Lower Limit of Quantitation (LLOQ) for All 4 Primary Test Strains Combined, Percentage of Participants With Fold Rise >=4 in hSBA for Each of the 4 Primary MenB Test Strains and 3 more. Started Apr 2017; status: completed.